Stockreport

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potent...

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placeboConsistent data acros [Read more]